Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Consensus Rating of “Buy” by Brokerages

Sarepta Therapeutics, Inc. (NASDAQ:SRPTGet Rating) has received a consensus rating of “Buy” from the fifteen research firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and nine have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $115.17.

SRPT has been the topic of a number of recent research reports. Morgan Stanley decreased their price objective on Sarepta Therapeutics from $80.00 to $77.00 and set an “equal weight” rating on the stock in a research report on Tuesday, April 12th. Needham & Company LLC reiterated a “buy” rating and issued a $150.00 price objective on shares of Sarepta Therapeutics in a research report on Tuesday, January 11th. Zacks Investment Research lowered Sarepta Therapeutics from a “hold” rating to a “sell” rating and set a $81.00 price objective on the stock. in a research report on Tuesday, April 26th. Barclays decreased their price objective on Sarepta Therapeutics from $125.00 to $104.00 in a research report on Wednesday, March 2nd. Finally, Royal Bank of Canada increased their price objective on Sarepta Therapeutics from $145.00 to $150.00 and gave the company an “outperform” rating in a research report on Wednesday, March 2nd.

SRPT stock opened at $72.32 on Monday. Sarepta Therapeutics has a 1-year low of $61.31 and a 1-year high of $101.24. The firm has a market cap of $6.33 billion, a P/E ratio of -14.07 and a beta of 1.30. The business’s 50 day moving average is $79.63 and its 200-day moving average is $80.19. The company has a current ratio of 5.75, a quick ratio of 5.34 and a debt-to-equity ratio of 1.18.

Sarepta Therapeutics (NASDAQ:SRPTGet Rating) last released its quarterly earnings results on Tuesday, March 1st. The biotechnology company reported ($1.42) EPS for the quarter, topping the Zacks’ consensus estimate of ($1.51) by $0.09. The business had revenue of $201.50 million for the quarter, compared to analyst estimates of $198.48 million. Sarepta Therapeutics had a negative return on equity of 69.28% and a negative net margin of 59.67%. Sarepta Therapeutics’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same period in the prior year, the company earned ($2.40) EPS. Sell-side analysts forecast that Sarepta Therapeutics will post -5.12 EPS for the current year.

Institutional investors have recently modified their holdings of the stock. Xponance Inc. raised its stake in Sarepta Therapeutics by 9.0% during the 4th quarter. Xponance Inc. now owns 9,332 shares of the biotechnology company’s stock worth $840,000 after buying an additional 772 shares during the period. Moors & Cabot Inc. acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth $51,000. Summit Wealth & Retirement Planning Inc. acquired a new stake in Sarepta Therapeutics during the 3rd quarter worth $215,000. Rafferty Asset Management LLC raised its stake in Sarepta Therapeutics by 46.2% during the 3rd quarter. Rafferty Asset Management LLC now owns 44,359 shares of the biotechnology company’s stock worth $4,102,000 after buying an additional 14,027 shares during the period. Finally, Bank of Nova Scotia increased its holdings in Sarepta Therapeutics by 3,188.5% during the 3rd quarter. Bank of Nova Scotia now owns 209,118 shares of the biotechnology company’s stock worth $19,339,000 after purchasing an additional 202,759 shares in the last quarter. 75.64% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile (Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Further Reading

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.